Browse the corpus
Walk the Even Hospital Database by book and chapter — the raw source passages that ground Ask, DDx, and the rest.
3 passages
Daunorubicin : 60 to 90 mg/m 2 intravenous push on each of the first 3 days of treatment "Standard 7+3" induction regimen resulting in approximately 60 to 80 percent remission rate and acceptable toxicity in patients under 60 years old Cytarabine (HDAC) plus daunorubicin
Daunorubicin : 45 mg/m 2 intravenous push for 3 days following cytarabine Yields a 90 percent remission rate; however, substantial toxicity precludes postremission therapy in a high proportion of patients Cytarabine plus idarubicin
Idarubicin : 12 to 13 mg/m 2 IV push on each of first 3 days of treatment Has produced a greater remission rate (88 versus 70 percent) than cytarabine/daunorubicin in younger patients; appears superior to daunorubicin in patients with hyperleukocytosis; overall survival not clearly superior to "standard" regimen Overview of common induction therapy regimens for acute myeloid leukemia in younger adults. HDAC: high dose cytarabine.